We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$5.12B
1-Year Est. Return
314.02%
This Fund
S&P 500
This Quarter
Est. Return
+10.76%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$6.85B
AUM Growth
+$678M
(+11%)
Cap. Flow
-$502M
Cap. Flow
% of AUM
-7.33%
Top 10 Holdings %
Top 10 Hldgs %
43.77%
Holding
155
New
30
Increased
19
Reduced
23
Closed
29
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Outset Medical
OM
|
+$156M |
| 2 |
CRISPR Therapeutics
CRSP
|
+$119M |
| 3 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$90.9M |
| 4 |
Relay Therapeutics
RLAY
|
+$88.8M |
| 5 |
Coherus Oncology
CHRS
|
+$57.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ZGNX
Zogenix, Inc.
ZGNX
|
+$133M |
| 2 |
Kodiak Sciences
KOD
|
+$124M |
| 3 |
Neurocrine Biosciences
NBIX
|
+$68.6M |
| 4 |
VAPO
Vapotherm, Inc. Common Stock
VAPO
|
+$54.9M |
| 5 |
Iovance Biotherapeutics
IOVA
|
+$52.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 81.69% |
| 2 | Financials | 0.25% |
| 3 | Industrials | 0.17% |
| 4 | Materials | 0.13% |
| 5 | Communication Services | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MRTX
1
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $570M | 8.33% |
3,435,575
+664,525
| +24% | +$90.9M |
|
|
FOLD
2
DELISTED
Amicus Therapeutics
FOLD
| $355M | 5.18% |
25,122,048
-60,316
| -0.2% | -$879K |
|
|
3
Iovance Biotherapeutics
IOVA
$2.02B
| $332M | 4.85% |
10,085,632
-1,723,862
| -15% | -$52.8M |
|
|
GBT
4
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $320M | 4.67% |
5,800,996
-41,104
| -0.7% | -$2.61M |
|
5
BridgeBio Pharma
BBIO
$16.5B
| $252M | 3.67% |
6,706,268
| – | – |
|
6
Zymeworks
ZYME
$1.62B
| $205M | 2.99% |
4,400,999
+820,000
| +23% | +$28.2M |
|
|
MYOK
7
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $190M | 2.78% |
1,395,017
| – | – |
|
|
SWTX
8
DELISTED
SpringWorks Therapeutics
SWTX
| $166M | 2.42% |
3,481,148
-33,210
| -0.9% | -$1.41M |
|
|
ATNX
9
DELISTED
Athenex, Inc. Common Stock
ATNX
| $161M | 2.36% |
676,623
+100,000
| +17% | +$24M |
|
|
VBIV
10
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $157M | 2.3% |
1,834,749
| – | – |
|
|
11
Neurocrine Biosciences
NBIX
$18.2B
| $149M | 2.17% |
1,548,715
-592,695
| -28% | -$68.6M |
|
|
12
Outset Medical
OM
$86.8M
| $142M | 2.08% |
+189,855
| New | +$156M |
|
|
NVRO
13
DELISTED
NEVRO CORP.
NVRO
| $115M | 1.68% |
826,164
-73,808
| -8% | -$9.86M |
|
|
14
CRISPR Therapeutics
CRSP
$4.63B
| $112M | 1.64% |
+1,341,308
| New | +$119M |
|
|
15
Relay Therapeutics
RLAY
$3.95B
| $99.2M | 1.45% |
+2,329,407
| New | +$88.8M |
|
16
MeiraGTx Holdings
MGTX
$1.07B
| $85.2M | 1.24% |
6,433,277
| – | – |
|
|
QTNT
17
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $83.3M | 1.22% |
405,020
+72,794
| +22% | +$18.9M |
|
|
ALBO
18
DELISTED
Albireo Pharma Inc
ALBO
| $78.8M | 1.15% |
2,360,139
+400,000
| +20% | +$11.7M |
|
|
IMMU
19
DELISTED
Immunomedics Inc
IMMU
| $77.6M | 1.13% |
912,140
+550,000
| +152% | +$27.8M |
|
20
Novavax
NVAX
$1.2B
| $76.7M | 1.12% |
707,715
+357,715
| +102% | +$43.6M |
|
|
21
Coherus Oncology
CHRS
$217M
| $66.7M | 0.97% |
3,636,485
+3,091,200
| +567% | +$57.5M |
|
22
Korro Bio
KRRO
$144M
| $62.6M | 0.91% |
65,130
+4,444
| +7% | +$4.77M |
|
|
FMTX
23
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $62.3M | 0.91% |
1,250,000
| – | – |
|
|
24
Kodiak Sciences
KOD
$2.42B
| $61.8M | 0.9% |
1,043,021
-2,470,551
| -70% | -$124M |
|
|
BPMC
25
DELISTED
Blueprint Medicines
BPMC
| $61.6M | 0.9% |
664,574
-24,050
| -3% | -$1.85M |
|
Similar funds
BG
TAM
CIA
AC
EIC
CIC
CS
NC
Perceptive Advisors's Q3 2020 Portfolio in Review
As of Q3 2020, Perceptive Advisors held 155 positions worth $6.85B, up 11% from $6.17B the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Perceptive Advisors withdrew a net $502M in Q3 2020, closing 29 positions and reducing 23 holdings. Its most notable exit was Zogenix, Inc., an estimated $133M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 82% a quarter earlier, followed by Financials and Industrials.
Against the trend, Perceptive Advisors opened a new position in Outset Medical worth $142M.
- Perceptive Advisors's largest Q3 2020 buy was Outset Medical: 189,855 shares worth $142M.
- Perceptive Advisors added most to Mirati Therapeutics, Inc. Common Stock in Q3 2020, an estimated $90.9M increase.
- Perceptive Advisors's biggest Q3 2020 reduction was Kodiak Sciences, cutting an estimated $124M.
- Perceptive Advisors fully exited Zogenix, Inc. in Q3 2020, selling an estimated $133M.
- Perceptive Advisors's ten largest holdings make up 44% of its $6.85B portfolio in Q3 2020.
- Perceptive Advisors opened 30 new positions and closed 29 in Q3 2020.
- Perceptive Advisors's portfolio value rose 11% quarter-over-quarter to $6.85B.
Based on Perceptive Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.